Plan strength, balance, and aerobic exercise together
Multicomponent exercise tailored to the individual’s health is an important foundation of frailty care, helping preserve mobility and everyday function.
OSANG SPECIALTY CENTER
Stem Cell Clinic
A Clear Guide to Healthy Aging and Frailty Research
Anti-aging stem cell research:
what has been established so far?
Current human studies do not show that aging itself can be reversed. They examine mobility, strength, physical function, quality of life, and short-term safety in people with aging-related frailty. Here, we review findings from external studies alongside their remaining limitations.
external thesis×Results commentary
Understanding Anti-aging Stem Cell Research
Human studies examine frailty and physical function—
not “rejuvenation.”
The studies assessed adults with aging-related frailty, not whether healthy people could become younger. They examined walking, balance, strength, fatigue, quality of life, inflammation-related markers, and adverse events.
The material below is a plain-language summary of published external research. It is not a report of treatment outcomes at OSANG Neurosurgery and does not establish efficacy or an indication for anti-aging use.
Things to know first
Established frailty care and cellular research should be considered separately.
Current frailty care is based on exercise, nutrition, medication review, and management of underlying conditions. Stem cell research is not an established anti-aging standard of care and does not replace these measures.
Assess nutritional status and chronic conditions together
Check for weight loss and undernutrition, and review whether medical conditions or medications may be contributing to fatigue, dizziness, or reduced strength.
A signal of potential benefit is not established efficacy
Early- and mid-phase trial results alone cannot establish reversal of aging, longer life, or the same benefit for everyone.
How to view study resultsLook beyond the numbers—
Look beyond the numbers—
consider the study design as well.
The source and dose of mesenchymal stromal cells (MSCs), number of administrations, control groups, blinding, and follow-up periods differ across studies, so their results cannot be compared as though they evaluated the same treatment.
Check whether participants met frailty criteria rather than simply being healthy older adults
People who merely share the same age are not equivalent to patients with frailty who have reduced walking ability and strength and greater fatigue; their starting points differ.
Check whether the study used a placebo and blinding
Randomization, placebo control, and blinding help prevent participants’ motivation or assessors’ expectations from influencing the results.
Assess whether changes in walking distance and test scores translated into daily-life benefits
Larger, dedicated studies are also needed to determine whether long-term outcomes such as falls, hospitalization, and disability are reduced.
Potential signals reported in the current literature
- In some randomized trials, six-minute walking distance and Short Physical Performance Battery scores improved relative to the control group.
- Changes were also reported in grip strength, fatigue, quality of life, and some inflammation-related markers.
- In the trials summarized here, no events judged to be serious adverse events related to the investigational product were reported.
What remains uncertain
- No evidence has established that these interventions reverse aging, reduce biological age, or extend lifespan.
- It has not been established whether they reduce long-term clinical outcomes such as falls, fractures, hospitalization, disability, or death.
- Because cell sources and doses differ, larger studies are needed to determine the optimal approach, duration of any benefit, and rare long-term adverse events.
3 randomized trials · 208 participants in total · Systematic review · 2026
The three studies showed potential signals,
but their effect sizes could not be pooled.
This systematic review searched databases from inception through April 15, 2026, and included only randomized trials in aging-related frailty. No meta-analysis was performed because cell sources, doses, populations, and assessment methods differed. The Nguyen study published in eBioMedicine in 2026 after the search cutoff was not included in this review.
- How many trials were reviewed?
- 3 randomized controlled trials
- How many participants were included?
- 208 participants in total
- What outcomes were examined?
- Mobility · Physical function · Quality of life · Inflammation · Safety
- Were the results pooled?
- No meta-analysis because of substantial differences among studies
Randomized controlled trials included3 trialsStudies of bone-marrow- or umbilical-cord-tissue-derived MSCs
Included studies3 trials
Total participants included208 participants in totalStudy size and design varied
Total participants208 participants
Pooled effect estimateNot calculatedResults were not reduced to a single estimate because the studies differed substantially
research 01
If you solve it easily,
You can look at the result like this.
Some trials reported signals of improvement in walking, physical function, quality of life, or inflammation-related markers, but these were not reproduced consistently across doses, time points, and outcomes. There were only three studies and their methods differed; the review authors judged all three trials to raise some concerns regarding risk of bias.
Original sourceView the original text and research information
Systematic Review of Randomized MSC Trials for FrailtyInternational Journal of Molecular Sciences · 2026 · 3 RCTsThe absence of reported treatment-related serious adverse events does not establish safety with respect to rare adverse effects or long-term use. Nor does it mean that no serious events or deaths occurred during the studies. For example, in the phase 2b trial, one death occurred in the treatment group and one in the placebo group, but neither was judged related to the investigational product. Reductions in falls, hospitalization, disability, or death have also not been demonstrated.
Phase 2b · 148 treated · Randomized · Double-blind · Placebo-controlled · 2026
Six-minute walking distance differed in some dose groups at 9 months,
but the individual comparison of the highest dose versus placebo at 6 months was not statistically significant.
This dose-ranging trial enrolled adults aged 70–85 with frailty. Participants received a single intravenous infusion of allogeneic bone-marrow-derived MSCs from young donors, with four dose groups compared against placebo.
- How many people participated?
- 148 treated · 143 included in the modified intention-to-treat analysis
- How were participants assigned?
- Randomized to one of 4 dose groups or placebo
- What intervention was given?
- Single intravenous infusion of 25–200 million allogeneic bone-marrow-derived MSCs
- When were outcomes assessed?
- Primary assessment at 6 months · Additional assessment at 9 months
Six-minute walking distance at 6 months · Difference between the 200-million-cell and placebo groups+41.3m95% CI −2.4 to 84.9 m · p=.0635 · Individual comparison not statistically significant
Difference versus placebo+41.3m
Six-minute walking distance at 9 months · Difference between the 200-million-cell and placebo groups+63.4m95% CI 17.1 to 109.6 m · p=.0077
Difference versus placebo+63.4m
Grip strength and 4-meter walking speedNo clear differenceNot all physical-function measures improved
research 02
If you solve it easily,
You can look at the result like this.
The prespecified 6-month dose–response analysis showed a signal, but the confidence interval for the individual comparison between the 200-million-cell and placebo groups included no difference. At 9 months, the 50-million- and 200-million-cell groups differed from placebo, but findings at a single time point cannot establish a sustained effect.
Original sourceView the original text and research information
Phase 2b Trial of Laromestrocel for FrailtyCell Stem Cell · 2026 · PMID 41747733Clinical trial registrationClinicalTrials.gov · NCT03169231Each dose group was small, and the 200-million-cell group included 16 participants. People with dementia were excluded, and sex distribution differed among some groups. NIH/NIA funding was awarded to the developer, Longeveron, and several authors were employees, consultants, board members, or shareholders of the company. Independent large-scale replication is needed.
Phase 2 · 147 analyzed · Randomized · Open-label · Assessor-blinded · 2026
Differences in physical-function scores, walking, and strength
were reported at 9 months.
Adults aged 60–85 with frailty were assigned to two groups. One group received two intravenous infusions of allogeneic umbilical-cord-derived MSCs three months apart, while both groups received nutritional supplements.
- How many participants were analyzed?
- 147 participants · 73 in the MSC group / 74 in the comparison group
- Was blinding used?
- Participants and clinicians were unblinded · Outcome assessors were blinded
- What intervention was given?
- Allogeneic umbilical-cord-derived MSCs, 1.5 million cells/kg · 2 infusions, 3 months apart
- When were outcomes assessed?
- Followed for 9 months
SPPB physical-function score at 9 months · Between-group difference+0.8 points95% CI 0.3 to 1.3 points based on Table 3 · Internally inconsistent with the +1.1-point value stated in the paper’s Summary
Difference versus the comparison group+0.8 points
Grip strength at 9 months · Between-group difference+2.7kg95% CI 1.1 to 4.4 kg
Difference versus the comparison group+2.7kg
Pulmonary function and cardiac ejection fractionNo between-group differenceNot all physiological measures changed
research 03
If you solve it easily,
You can look at the result like this.
Between-group differences were reported in physical function and some daily-life measures. However, participants and clinicians knew which treatment was given, and the comparison group received nutritional supplements without a placebo infusion, so expectancy effects cannot be ruled out.
Original sourceView the original text and research information
Phase 2 Trial of Umbilical-Cord-Derived MSCs for FrailtyeBioMedicine · 2026 · PMID 42019090Clinical trial registrationClinicalTrials.gov · NCT04919135This was a single-center, open-label phase 2 study, and nine months of follow-up is insufficient to judge durability or rare adverse events. Changes in cellular-senescence-related markers appeared at only one time point and cannot be interpreted as reversal of aging. Anticoagulant and antihistamine premedication was also given before cell infusion, so the safety findings must be interpreted within that protocol.